For thousands of individuals suffering from hallux rigidus, or big toe arthritis, the Cartiva Synthetic Cartilage Implant was marketed as a revolutionary breakthrough. It promised to provide a minimally invasive alternative to traditional toe fusion surgery, allowing patients to maintain their range of motion while finding relief from chronic pain. However, for many, this promise has transitioned into a medical and financial nightmare. As reports of high failure rates and severe complications have mounted, a significant wave of litigation has emerged. Understanding the details of the cartiva implant lawsuit is essential for any patient currently living with the device or facing the prospect of corrective surgery.
The Design Flaw and Failure Mechanism
The Cartiva implant is a small, gel-like plug made of a proprietary hydrogel designed to mimic natural human cartilage. It is intended to sit within the big toe joint, providing a cushion that prevents bones from rubbing together. The core of the legal claims against the manufacturer, Stryker Corporation—which acquired the device’s original makers—centers on a fundamental design defect. Plaintiffs allege that the hydrogel material is prone to shrinking, dehydrating, and degrading once inside the human body.
When the implant shrinks or loses its structural integrity, it often becomes loose or shifts from its intended position, a process known as migration. In many cases, the device can actually sink into the surrounding bone, a complication called subsidence. These failures don’t just return the patient to their original state of arthritic pain; they often cause new, more debilitating issues, including nerve damage, bone erosion, and the formation of painful cysts. Instead of preserving mobility, a failing Cartiva implant can leave a patient with less function and more agony than they had before the initial procedure.
The Path to Revision Surgery
For patients experiencing Cartiva failure, the physical symptoms are often undeniable. Many report a grinding sensation in the joint, persistent swelling, and a return of sharp, stabbing pain that makes walking almost impossible. Because the failing implant can cause bone loss or “pitting” in the joint, the remedy is rarely a simple fix. Most patients with a failed Cartiva device must undergo revision surgery.
In the majority of these cases, the failed implant is removed, and the surgeon must perform the very procedure the patient hoped to avoid: a toe fusion. During a fusion, the remaining bone is cleared of the damaged implant and spurs, and the joint is permanently locked together with plates and screws. This effectively eliminates pain but results in a permanent loss of motion in the big toe. The transition from a “mobile” implant to a permanent fusion is a significant life change, often requiring extensive rehabilitation and a permanent adjustment to the patient’s gait and activity levels.
Conclusion
The Cartiva implant lawsuit is a stark reminder of the risks inherent in medical device innovation when safety data is not transparently shared. For patients who trusted this technology to restore their active lifestyles, the failure of the device has been a profound betrayal of that trust. As the legal process moves forward into 2026, the goal remains twofold: to provide financial restitution for those who have suffered and to ensure that medical device manufacturers are held to the highest standards of honesty and accountability. By staying informed and taking proactive steps, patients can better navigate this difficult chapter and move toward a future free from chronic pain.
Best Legal Advice 